## Anticoagulant Agents – Oral and Subcutaneous

**Effective 01/10/2013**  
**Revised 01/08/2015**

### Preferred Agents

Available with Clinical Edit

- Clopidogrel
- Aggrenox®
- Ticloidipine
- Dipyridamole
- Warfarin
- Pradaxa®
- Xarelto®
- Lovenox®
- Fragmin®
- Eliquis®

### Non-Preferred Agents

Available with Clinical Edit

- Pletal®
- Cilostazol
- Effient®
- Brilinta®
- Persantine®
- Coumadin®
- Enoxaparin
- Innohep®
- Fondaparinux
- Plavix®
- Zontivity™
- Arixtra®

### Approval Criteria

**For All Appropriate Anticoagulants**

**For Cardiothrombotic Events, Stroke Events and Related Events**

- Aspirin therapy first-line but platelet inhibitor therapy will be approved if:
  - ADE/ADR to aspirin **OR**
  - a therapeutic failure to aspirin is identified (i.e., at least one aspirin claim in the last year) **OR**
  - May be started at the same time, but the aspirin claim must be processed prior to antiplatelet claim

- Clopidogrel (Plavix)
  - STEMI with or without stent
  - U/VNSTEMI invasively or noninvasively managed with or without stent
  - Antithrombotic therapy
  - Percutaneous Coronary Intervention

- A documented approval diagnosis or procedure as listed below (see appendices) allows access to preferred drugs without aspirin trial and failure

- Cilostazol (Pletal) – available first-line for intermittent claudication
- Prasugrel (Effient) – available first-line for MI with stent
- Ticagrelor (Brilinta) – available first-line for MI with stent
- Appropriate Diagnosis
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin</td>
<td>Coumadin</td>
<td>• STEMI w/o Stent&lt;br&gt;• STEMI with Stent&lt;br&gt;• NSTEMI w/o Stent&lt;br&gt;• NSTEMI with Stent&lt;br&gt;• Non-Q wave MI&lt;br&gt;• MI&lt;br&gt;• DVT Treatment&lt;br&gt;• DVT Prophylaxis&lt;br&gt;• PE Treatment&lt;br&gt;• PE Prophylaxis&lt;br&gt;• Non-valvular Atrial Fibrillation&lt;br&gt;• Atrial Fibrillation&lt;br&gt;• Stroke due to Thrombosis&lt;br&gt;• TIA</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Aspirin</td>
<td>• STEMI w/o Stent&lt;br&gt;• STEMI with Stent&lt;br&gt;• NSTEMI w/o Stent&lt;br&gt;• NSTEMI with Stent&lt;br&gt;• Non-Q wave MI&lt;br&gt;• MI&lt;br&gt;• PCI&lt;br&gt;• Unstable Angina&lt;br&gt;• Non-valvular Atrial Fibrillation&lt;br&gt;• Atrial Fibrillation&lt;br&gt;• Stroke due to Thrombosis&lt;br&gt;• TIA&lt;br&gt;• Coronary Artery Bypass Grafts</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>Plavix</td>
<td>• STEMI w/o Stent&lt;br&gt;• STEMI with Stent&lt;br&gt;• NSTEMI w/o Stent&lt;br&gt;• NSTEMI with Stent&lt;br&gt;• Non-Q wave MI&lt;br&gt;• MI&lt;br&gt;• PCI&lt;br&gt;• Unstable Angina&lt;br&gt;• Non-valvular Atrial Fibrillation&lt;br&gt;• Peripheral Artery Disease&lt;br&gt;• Stroke due to Thrombosis&lt;br&gt;• Coronary Artery Bypass Grafts</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>Lovenox</td>
<td>• STEMI w/o Stent&lt;br&gt;• Non-Q wave MI&lt;br&gt;• PCI&lt;br&gt;• Unstable Angina&lt;br&gt;• DVT Treatment&lt;br&gt;• DVT Prophylaxis with Abdominal Surgery or Joint Replacement&lt;br&gt;• PE Treatment&lt;br&gt;• PE Prophylaxis with Abd Surg or Joint Replacement</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>Fragmin</td>
<td>• Non Q-wave MI&lt;br&gt;• Unstable Angina&lt;br&gt;• DVT (Symptomatic extended treatment not acute)</td>
</tr>
<tr>
<td>Drug</td>
<td>Drug Name</td>
<td>Treatment Details</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Apixaban</td>
<td>Eliquis</td>
<td>• PE Treatment&lt;br&gt;• DVT Treatment&lt;br&gt;• PE Treatment&lt;br&gt;• DVT and PE Prophylaxis with Hip or Knee Replacement Surgery&lt;br&gt;• Prophylaxis of recurrence of DVT and PE&lt;br&gt;• Non-valvular Atrial Fibrillation</td>
</tr>
<tr>
<td>Fondaprinux</td>
<td>Arixta</td>
<td>• DVT Treatment&lt;br&gt;• DVT Prophylaxis with Abdominal Surgery or Joint Replacement&lt;br&gt;• PE Treatment&lt;br&gt;• PE Prophylaxis with Abdominal Surgery or Joint Replacement</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>Xarelto</td>
<td>• DVT Treatment&lt;br&gt;• DVT and PE Prophylaxis with Hip or Knee Replacement&lt;br&gt;• PE Treatment&lt;br&gt;• Prophylaxis of recurrence of DVT and PE&lt;br&gt;• Non-valvular Atrial Fibrillation</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Pradaxa</td>
<td>• DVT and PE Treatment after 5-10 days treated with parenteral anticoagulation&lt;br&gt;• Prophylaxis of recurrence of DVT and PE&lt;br&gt;• Non-valvular Atrial Fibrillation</td>
</tr>
<tr>
<td>Prasugrel</td>
<td>Effient</td>
<td>• STEMI with Stent&lt;br&gt;• NSTEMI with Stent&lt;br&gt;• Unstable Angina</td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>Brilinta</td>
<td>• STEMI with Stent&lt;br&gt;• NSTEMI with Stent&lt;br&gt;• Unstable Angina</td>
</tr>
<tr>
<td>Ticlopidine</td>
<td>Ticlopidine</td>
<td>• Stroke due to Thrombosis&lt;br&gt;• Stent Thrombosis, adjunctive therapy</td>
</tr>
<tr>
<td>Vorapaxar</td>
<td>Zontivity</td>
<td>• MI&lt;br&gt;• Peripheral Artery Disease – no history of stroke, TIA or ICH</td>
</tr>
<tr>
<td>Cilostazol</td>
<td>Pletal</td>
<td>• PCI (not able to take aspirin or clopidogrel)&lt;br&gt;• Intermittent Claudication</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>Persantine</td>
<td>• Prophylaxis of Post Op Thrombus with Cardiac Valve Replacement</td>
</tr>
<tr>
<td>Dipyridamole/Aspirin</td>
<td>Aggrenox</td>
<td>• Stroke due to thrombosis&lt;br&gt;• TIA</td>
</tr>
</tbody>
</table>
Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents
  - Documented trial period for preferred agents
  - Documented ADE/ADR to preferred agents
- Documented compliance on current therapy regimen

**Denial Criteria**

- Lack of evidence of aspirin therapy in patient’s prescription claims history in the last year for clopidogrel, Aggrenox, Ticlopidine, Dipyridamole, Brilinta, **Effient** or Cilostazol
- Absence of any of the approval diagnoses or procedures
- Clopidogrel
  - Patients < 18 years of age
- **Aspirin/extended-release dipyridamole, ticlopidine, cilostazol**
  - Patients < 18 years of age
- **Effient**
  - Patients > than 75 years
  - Patients less than 132 lbs
  - History of stroke/TIA (subject to clinical consultant)
- Brilinta
  - Aspirin > 100 mg a day
- **Zontivity**
  - **Not currently on aspirin or clopidogrel**
  - **Cerebral hemorrhage**
- Lack of adequate trial on required preferred agents
- Drug Prior Authorization Hotline: (800) 392-8030